Adjuvant chemotherapy in patients with newly diagnosed non-co-deleted anaplastic gliomas—a new standard

Many clinical trials in neuro-oncology have sought to define treatment paradigms for glioblastomas [World Health Organization (WHO) grade IV gliomas], the most common adult primary CNS malignancy. Substantially fewer have been performed in patients with newly diagnosed anaplastic (WHO grade III) gliomas, most likely reflecting the lower incidence of grade III gliomas. Fewer still have been large randomized clinical trials that have established standards of care.